Abstract
The global human immunodeficiency virus type 1 (HIV-1) epidemic is devastating many communities and a well tolerated and effective vaccine is urgently required. Several lines of evidence suggest that vaccine-induced protective immunity can be achieved. This evidence includes individuals shown to have natural immunity, and the partially effective immune responses that are generated during natural infection. However, the obstacles to HIV-1 vaccine development are enormous. The only substantially effective vaccine studied in pathogenic animalmodels (live, attenuated vaccines) is at present far too unsafe. The only HIV-1 vaccine to proceed to efficacy trials (an envelope protein approach) has been disappointing in its immunogenicity and efficacy in preliminary trials. The antigenic variability of HIV-1 strains is also a great obstacle. Unfortunately, commercial realities also do not favour the expensive development of HIV-1 vaccines required most urgently in less developed countries. Despite these obstacles, there is cause for cautious optimism. Better tolerated HIV-1 vaccine approaches are currently showing great promise in primate models and preliminary clinical trials. Many governments and the World Bank are now providing the political will and funding necessary to fast-track HIV-1 vaccine development. Given sufficient long term scientific and commercial commitment to the HIV-1 vaccine development process, it is ultimately likely that a preventative HIV-1 vaccine will emerge.
Article PDF
Similar content being viewed by others
References
Piot P. The science of AIDS: a tale of two worlds. Science 1998; 280: 1844–5
Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307–11
Phoolcharoen W. HIV/AIDS prevention in Thailand: success and challenges. Science 1998; 280: 1873–4
Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355–8
Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183–8
Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3: 205–11
Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997; 71: 7719–27
Kent SJ, Greenberg PD, Hoffman MC, et al. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. J Immunol 1997; 158: 807–15
Mestecky J, Jackson S. Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines. J Clin Immunol 1994; 14: 259–72
Letvin NL. Progress in the development of an HIV-1 vaccine. Science 1998; 280: 1875–80
Clements JE, Montelaro RC, Zink MC, et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995; 69: 2737–44
Haigwood NL, Watson A, Sutton WF, et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett 1996; 51: 107–14
Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204–10
Wyand MS, Manson KH, Garcia-Moll M, et al. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996; 70: 3724–33
Burton DR. Avaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A 1997; 94: 10018–23
LaCasse RA, Follis KE, Trahey M, et al. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999; 283: 357–62
Norley S, Beer B, Binninger-Schinzel D, et al. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 1996; 219: 195–205
Connor RI, Montefiori DC, Binley JM, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998; 72: 7501–9
Montelaro RC, Cole KS, Hammond SA. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 1998; 14 Suppl. 3: S255–9
Johnson RP, Siliciano RF, McElrath MJ. Cellular immune responses to HIV-1. Aids 1998; 12: S113–20
Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337: 1267–74
Kent SJ, Woodward A, Zhao A. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques. J Infect Dis 1997; 176: 1188–97
Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650–5
Prince AM, Andrus L. AIDS vaccine trials in chimpanzees. Science 1998; 282: 2195–6
Kent SJ, Zhao A, Best SJ, et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998; 72: 10180–8
Khabbaz RF, Heneine W, George JR, et al. Brief report: infection of a laboratory worker with simian immunodeficiency virus. N Engl J Med 1994; 330: 172–7
Almond NM, Heeney JL. AIDS vaccine development in primate models. Aids 1998; 12: S133–40
Heeney J, Akerblom L, Barnett S, et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 1999; 66: 189–95
Whatmore AM, Cook N, Hall GA, et al. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 1995; 69: 5117–23
Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5: 194–203
Desrosiers RC. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine. AIDS Res Hum Retroviruses 1994; 10: 331–2
Purcell DF, Broscius CM, Vanin EF, et al. An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol 1996; 70: 887–97
Boyer JD, Ugen KE, Wang B, et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997; 3: 526–32
Jayaraman KS. World Bank will lend more money to India for AIDS. Nat Med 1998; 4: 750
Dove A. International AIDS Vaccine Initiative advances AIDS vaccine research. Nat Med 1999; 5: 5
Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722–5
Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367–77
Fowke KR, Nagelkerke NJ, Kimani J, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348: 1347–51
Rowland-Jones SL, Dong T, Fowke KR, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998; 102: 1758–65
Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 59–64
Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209–16
Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157: 2168–73
Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988–91
Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report fromthe Sydney Blood Bank Cohort. N Engl J Med 1999; 340: 1715–22
Desrosiers RC, Lifson JD, Gibbs JD, et al. Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 1998; 72: 1431–7
Downs AM, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. European Study Group in Heterosexual Transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 388–95
Benson J, Chougnet C, Robert-Guroff M, et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol 1998; 72: 4170–82
Kent SJ, Hu SL, Corey L, et al. Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol 1996; 70: 4941–7
Hu SL, Abrams K, Barber GN, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255: 456–9
Hulskotte EG, Geretti AM, Osterhaus AD. Towards an HIV-1 vaccine: lessons from studies in macaque models. Vaccine 1998; 16: 904–15
Cole KS, Murphey-Corb M, Narayan O, et al. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol 1998; 72: 7852–9
Johnson RP, Glickman RL, Yang JQ, et al. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997; 71: 7711–8
Bogers WM, Niphuis H, ten Haaft P, et al. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. Aids 1995; 9: F13–8
Murphey-Corb M, Martin LN, Davison-Fairburn B, et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989; 246: 1293–7
Stott EJ. Anti-cell antibody inmacaques. Nature 1991; 353: 393
Le Grand R, Vogt G, Vaslin B, et al. Specific and non-specific immunity and protection of macaques against SIV infection. Vaccine 1992; 10: 873–9
Stott J, Hu SL, Almond N. Candidate vaccines protect macaques against primate immunodeficiency viruses. AIDS Res Hum Retroviruses 1998; 14 Suppl. 3: S265–70
Mooij P, van der Kolk M, Bogers WM, et al. A clinically relevant HIV-1 subunit vaccine protects rhesusmacaques from in vivo passaged simian-human immunodeficiency virus infection. Aids 1998; 12: F15–22
Stott EJ, Almond N, Kent K, et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Virol 1998; 79: 423–32
Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173: 340–8
Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14 Suppl. 3: S325–31
Connor RI, Korber BT, Graham BS, et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998; 72: 1552–76
Cairns JS, Sarver N. New viral vectors for HIV vaccine delivery. AIDS Res Hum Retroviruses 1998; 14: 1501–8
Gurvich EB. The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine. Vaccine 1992; 10: 96–7
Shen L, Chen ZW, Miller MD, et al. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991; 252: 440–3
Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A 1993; 90: 1882–6
Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337: 567–72
Corey L, McElrath MJ, Weinhold K, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177: 301–9
Egan MA, Pavlat WA, Tartaglia J, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995; 171: 1623–7
Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997; 3: 651–8
Yasutomi Y, Koenig S, Haun SS, et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993; 150: 3101–7
Lu S, Arthos J, Montefiori DC, et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996; 70: 3978–91
Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273: 352–4
Kim JJ, Trivedi NN, Nottingham LK, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28: 1089–103
Kim JJ, Nottingham LK, Wilson DM, et al. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 1998; 16: 1828–35
Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998; 392: 408–11
Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351: 1320–5
MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92–100
Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999; 5: 526–34
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joy, A.K., Dale, C.J. & Kent, S.J. Can HIV Infection be Prevented with a Vaccine?. Drugs in R&D 1, 431–440 (1999). https://doi.org/10.2165/00126839-199901060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901060-00001